NBIX250117P90000
- 0.00
- 0.000.00%
Neurocrine Biosciences Newsroom
Neurocrine Is Maintained at Overweight by Barclays
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $182
TD Cowen Reaffirms Their Buy Rating on Neurocrine (NBIX)
Neurocrine Biosciences Analyst Ratings
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $185
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $148 to $190
Wedbush Reaffirms Their Buy Rating on Neurocrine (NBIX)
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $160 to $190
Neurocrine Price Target Maintained With a $190.00/Share by HC Wainwright & Co.
Neurocrine Biosciences Analyst Ratings
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
Neurocrine (NBIX) Receives a Hold From RBC Capital
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $166
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $160